Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The Company is currently developing a drug technology, LTI-03, for the treatment of Idiopathic Pulmonary Fibrosis. Preclinical evidence suggests that LTI-03 sustains survival of damaged lung cells throughout this novel mechanism of action, in addition to slowing and resolving the downstream progress of fibrosis.
|Employees (est.) (Feb 2019)||9||(-10%)|
Lung Therapeutics total Funding
Lung Therapeutics latest funding size
Time since last funding
|2 years ago|
Lung Therapeutics investors
|Bios Partners, Texas Venture Labs, UT Horizon Fund|
When was Lung Therapeutics founded?
Lung Therapeutics was founded in 2013.
Who are Lung Therapeutics key executives?
Lung Therapeutics's key executives are Brian Windsor, Steven Idell and Andrew Mazar.
How many employees does Lung Therapeutics have?
Lung Therapeutics has 9 employees.
Who are Lung Therapeutics competitors?
Competitors of Lung Therapeutics include Opiant Pharmaceuticals, IntelGenx and Generex Biotechnology.
Where are Lung Therapeutics offices?
Lung Therapeutics has an office in Austin.
How many offices does Lung Therapeutics have?
Lung Therapeutics has 1 office.